PRM2 Evidence-based prescribing: using existing data on benefits and harms to choose among multiple drugs  by Naci, H. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A181
able that for subjects showing severe symptoms, the quality of life and the sleep 
is also improved.
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Hung M.C.1, Lai W.W.2, Hwang J.S.3, Wang J.D.4
1Department of Public Health, National Cheng Kung University Medical College, Tainan, Taiwan, 
2Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National 
Cheng Kung University, Tainan, Taiwan, 3Institute of Statistical Science, Academia Sinica, Taipei, 
Taiwan, 4National Cheng Kung University College of Medicine, Tainan, Taiwan
Objectives: We conducted this study to estimate the saving of loss-of-QALE 
(quality-adjusted life expectancy) for 9 different cancers and validated them with 
estimation of EYLL (expected years of life loss) plus expected years of living with 
disability (EYLD). MethOds: 395,330 patients with pathologically verified can-
cer registered in the National Cancer Registry in Taiwan between 1998 and 2007 
were used to estimate the survival functions and extrapolate to lifetime through 
a semi-parametric method. EYLL for cancer was calculated by subtracting the life 
expectancy of the cancer cohort from that of the age-and sex-matched general 
population. A convenience sample of 6,189 measurements of EQ-5D was collected 
for utility values and proportions of functional disability to estimate their QALE and 
EYLD. The loss of QALE for these patients was calculated by assuming a uniform 
utility of one for the age- and gender- matched reference subjects simulated from 
the hazard functions of vital statistics, and subtracting the QALE of these cancer 
cohorts. We also estimated the lifetime risks for different cancers with Cumulative 
incidence rates (CIR20-79) and multiplied with loss-of-QALE to obtain the expected 
impact. Results: EYLL plus EYLD were similar to loss-of-QALE. Male patients with 
esophageal cancer suffered the highest loss-of-QALE of 18.37 QALY (quality-adjusted 
life year), equivalent to 18.19 years of EYLL plus EYLD; those of female patients with 
lung cancer were 16.57 QALY and 17.1 years, respectively. After multiplied with 
the lifetime risk, liver cancer in male and breast cancer in female were expected 
to have the highest impact, or loss of 1.10-1.11 and 0.58-0.65 QALY or life-years, 
respectively. cOnclusiOns: Estimated EYLL plus EYLD are close to loss-of-QALE 
and both can be used for measuring impact of cancer prevention. Simultaneous 
consideration of lifetime risk would provide a more accurate estimate for compara-
tive risk assessment.
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Objectives: Even in cases where comparative clinical data exist, decision-makers 
often struggle to weigh the relative benefits and harms of multiple drugs. We pre-
sent the potential benefit of combining network meta-analysis (NMA) with multi-
criteria decision analysis (MCDA) in order to formalize the incorporation of clinical 
evidence and qualitative preferences into prescribing decisions. MethOds: Using a 
systematic review and NMA of cholesterol-lowering statins as a case study, we com-
pared the absolute risk of mortality, coronary and cerebrovascular events, myalgia, 
creatine kinase and transaminase elevations, and discontinuations due to adverse 
events associated with atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvas-
tatin, and simvastatin. We applied a structured benefit-risk model that allowed 
evidence on multiple outcomes to be combined using qualitative preferences, 
assuming that the effect of statins on preventing mortality was more important 
than either major coronary or cerebrovascular events, which were in turn more 
important than any one of the harm outcomes. Results: There were 184 ran-
domized controlled trials of statins including 260,630 individuals. Our previous 
NMA found statistically detectable differences among individual statins in terms of 
both benefit and harm outcomes. When all outcomes were combined using MCDA, 
fluvastatin had a considerable probability of both being the best (41%) and worst 
(12%) statin, reflecting the uncertainty in its evidence base. In contrast, simvastatin 
had a high probability of better ranks (36%) with a negligible probability of ranking 
worst (~1%). cOnclusiOns: Clinical evidence can be combined with qualitative 
preferences at point-of-care settings when making prescribing decisions. The com-
bination of NMA with MCDA holds the promise to introduce more transparency to 
the decision-making process and potentially increase the relevance and informative 
value of existing evidence for prescribing decisions. Adopting such an approach for 
cholesterol-lowering therapy suggests that simvastatin may potentially have the 
most favorable benefit-harm profile among statins.
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A COMPARISON Of 3 ASSESSMENTS IN THE TREATMENT Of ROSACEA IN THE 
CONTExT Of A COMPARATIVE EffECTIVENESS STUDy
Kendall J., Winkelman W.
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Objectives: A comparative crossover study was conducted to assess the efficacy 
of brimonidine gel 0.33% (BG) vs azelaic acid gel 15% (AG) for the treatment of per-
sistent facial erythema of rosacea using three assessments: clinician’s erythema 
assessment (CEA), patient self-assessment (PSA), and chromameter instrumenta-
tion. MethOds: This was a multicenter, randomized, controlled, double-masked 
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Objectives: The objectives of this study were to describe the COPD population 
and treatment patterns, to estimate treatment adherence, and to compare medi-
cation cost, in a real life setting, using the Régie de l’assurance maladie du Québec 
(RAMQ) database. MethOds: Patients who had a diagnosis of COPD (ICD-9 codes: 
4910-4929, 4960-4969), or who received at least one script of a COPD medication 
from January 1st 2010 to January 31st 2013 were selected. Patient’s characteristics, 
drug utilization patterns, adherence, and costs were analyzed. Results: Among 
patients with a COPD diagnosis, 3,015 patients were treated with LABA (long-acting 
beta-agonists); 12,099 with LAAC (long-acting anticholinergics); and 11,029 with 
a fixed-combination of LABA/inhaled corticosteroids (ICS). A proportion of 26.1%, 
23.6%, and 31.0% of LABA, LAAC, and LABA/ICS users, respectively, had a mixed 
diagnosis with asthma. More than 80% of patients on long-acting agent treat-
ments used more than one medication in concomitance. The results showed a 
high usage of ICS in concomitance with LAAC (20.3% in free-combination; 53.2% 
in fixed-combination). In incident users (no COPD medication in the previous year) 
treated with triple therapy LAAC+LABA/ICS (n= 125), average time to triple therapy 
was less than six months. The compliance, estimated over up to 1-year period, of 
long-acting COPD medications given more than once daily was 41.4%. The switch 
to once-daily medication was associated with a compliance of 61.4%. The com-
pliance of the medications used before the switch to once-daily medication was 
30.5%. The persistence of long-acting COPD medications given more than once 
daily was 72.3% at 6 months. At 6 months, the persistence of once-daily medication 
was 76.7%. The mean monthly cost per medication was CDN$46.65 (SD= 39.21) for 
LABA users, CDN$63.14 (SD= 121.79) for LAAC users, and CDN$96.20 (SD= 162.43) 
for LABA/ICS users. cOnclusiOns: Medication given once daily was associated 
with a higher level of treatment compliance.
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ITAlIAN CASE
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Objectives: Allergic rhinoconjuntivitis is a global health problem, and many 
studies have shown an important increase in the disease prevalence in the last 
20 years. Allergen specific immunotherapy (SIT) is the only available treatment 
for the underlying cause of the disease. At present, few economic evaluations are 
available for Italy. The present study is focused on the cost effectiveness of SIT in 
Italy, considering the fragmented reimbursement policies in different Regions of 
the Country. MethOds: A review of the literature on the pharmaco-economy of 
immunotherapy for allergic rhinoconjuntivitis with a special focus on Italy (costs 
taken from Italian formularies, tariffs and Diagnosis Related Groups, or DRG). 
Reimbursement values were taken from official regional resolutions Results: 
Treatment with SIT reduced by 38% symptomatic drugs consumption (whose costs 
are ranging from € 0.1 to € 0.5 per unit). Moreover, SIT reduced by 30% symptoms 
intensity (impacting on GPs and specialists visits, whose cost are ranging from € 13 
to € 18, respectively) and by 20% the development of allergic asthma (which implies € 
190 for one day of hospitalization). There are wide differences in SIT reimbursement 
across Italian Regions, ranging from 100% in 3, to various level of copayment in 7, 
down to no reimbursement in 10. cOnclusiOns: Overall, these data support the 
favorable impact of SIT on the medium-long term in front of a relative cost increase 
in the short term. This benefit is still not fully recognized in Italy where differences 
persist across regions in the access to SIT reimbursement.
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IMPACT, IN REAl lIfE CONDITIONS, Of THE USE Of A PURIfIER SPRAy ON 
AllERgy CARE IN DUST MITE AllERgIC SUbjECTS
Taieb C.1, Ripoll C.2
1CrééS, Paris, France, 2Naturactive, Castres, France
Objectives: The study has been set-up in order to evaluate in real life conditions 
the perceived efficacy of a spray containing essential oils on allergy-related-symp-
toms, day-sleepiness and QoL of allergic subjects. MethOds: Women-and-men 
with a known history of dust mite allergy were recruited in the study. They were 
asked to use in their house twice a day, the purifier spray for a period of 28days. 
The perceived efficacy was evaluated via self-validated questionnaires on allergy 
symptoms (discomfort generated by sneezing- itchy eyes-stuffy nose-nasal flow-
tiredness-ear itching), on daytime-sleepiness (Epworth-Sleepiness-Scale) and on 
QoL (SF12). For the study outcomes, each subject was evaluated at inclusion, at 
day7 and day28. The satisfaction through the CSQ8-questionnaire was also evalu-
ated at day28. Results: 42 subjects, with an history of allergy of 21.4±11.2years, 
were included. They present a symptom-score at inclusion of 6.63±3.5 which was 
significantly reduced after 7 days of spray use with a value of 3.87±2.4 (p< 0,0001). 
The improvement was confirmed at day28:1.85±1.6-(p< 0,0001). The data were also 
evaluated according to symptom severity, i.e.low, moderate or severe. For the mod-
erate or severe subpopulations, a significant improvement was observed on the 
symptoms score since 7days of spray use. Moreover, for the subjects showing severe 
symptoms, an improvement was also observed on daytime-sleepiness (p< 0,05) with 
the Epworth score going from 9.18 ±7.1 to 4.75 ±3.9 after 28days, and on the SF12 
mental dimension score (42.8 vs 48.2-p< 0,04) For the studied population the over-
all satisfaction evaluated was above 75% after 28days. cOnclusiOns: By using 
self-validated-questionnaires, the evaluation shows the interest of the use of the 
essential oils spray in allergy care for dust mite allergic subjects. The improvement 
on symptoms is observed whatever the severity of symptoms is, and it is notice-
